The higher percentage of GLP-1 RA and SGLT2i use in the groups with obesity after accounting for age and duration of diabetes suggests that doctors are aware of the weight loss benefit of these medications. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.